Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

Taro Kishi; Kenji Sakuma; Masakazu Hatano; Yuki Matsuda; Satoru Esumi; Nobumi Miyake; Itaru Miura; Hikaru Hori; Masaki Kato; Nakao Iwata

doi:10.1002/npr2.12376

Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

Taro Kishi
, Kenji Sakuma
, Masakazu Hatano
, Yuki Matsuda
, Satoru Esumi
, Nobumi Miyake
, Itaru Miura
, Hikaru Hori
, Masaki Kato
, Nakao Iwata

研究成果: ジャーナルへの寄稿 › 学術論文

抄録

INTRODUCTION: The question remains to be elucidated: "Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?" It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random-effects pairwise meta-analysis including these nine double-blind, randomized, placebo-controlled trials. METHODS: We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). RESULTS: Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = -0.20 (-0.27, -0.12), p

本文言語	英語
ジャーナル	Japanese Journal of Neuropsychopharmacology
DOI	https://doi.org/10.1002/npr2.12376
出版ステータス	出版済み - 30-08-2023

文献へのアクセス

10.1002/npr2.12376ライセンス: 指定なし

引用スタイル

@article{6a9ebe7376334cf5821e440877d764a4,

title = "Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.",

abstract = "INTRODUCTION: The question remains to be elucidated: {"}Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?{"} It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random-effects pairwise meta-analysis including these nine double-blind, randomized, placebo-controlled trials. METHODS: We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95\% confidence interval (95\% CI). RESULTS: Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95\% CI) = -0.20 (-0.27, -0.12), p ",

author = "Taro Kishi and Kenji Sakuma and Masakazu Hatano and Yuki Matsuda and Satoru Esumi and Nobumi Miyake and Itaru Miura and Hikaru Hori and Masaki Kato and Nakao Iwata",

note = "Is international journal: true",

year = "2023",

month = aug,

day = "30",

doi = "10.1002/npr2.12376",

language = "English",

journal = "Japanese Journal of Neuropsychopharmacology",

issn = "1340-2544",

}

TY - JOUR

T1 - Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

AU - Kishi, Taro

AU - Sakuma, Kenji

AU - Hatano, Masakazu

AU - Matsuda, Yuki

AU - Esumi, Satoru

AU - Miyake, Nobumi

AU - Miura, Itaru

AU - Hori, Hikaru

AU - Kato, Masaki

AU - Iwata, Nakao

N1 - Is international journal: true

PY - 2023/8/30

Y1 - 2023/8/30

N2 - INTRODUCTION: The question remains to be elucidated: "Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?" It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random-effects pairwise meta-analysis including these nine double-blind, randomized, placebo-controlled trials. METHODS: We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). RESULTS: Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = -0.20 (-0.27, -0.12), p

AB - INTRODUCTION: The question remains to be elucidated: "Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?" It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random-effects pairwise meta-analysis including these nine double-blind, randomized, placebo-controlled trials. METHODS: We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). RESULTS: Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = -0.20 (-0.27, -0.12), p

U2 - 10.1002/npr2.12376

DO - 10.1002/npr2.12376

M3 - Article

C2 - 37646475

SN - 1340-2544

JO - Japanese Journal of Neuropsychopharmacology

JF - Japanese Journal of Neuropsychopharmacology

ER -

Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

抄録

文献へのアクセス

フィンガープリント

引用スタイル